NEW YORK (GenomeWeb News) – The stocks of Agilent and Celera were upgraded today by two different analysts, but the market responded in very different ways with Agilent's shares surging and Celera's falling in afternoon trade.

Agilent's stock was upgraded to "outperform" from "neutral" by Credit Suisse analyst William Stein, who also upped his target price on the shares to $20 from $15. He cited the possibility of Agilent focusing more on its bio-analytical measurement business, which is not as susceptible to the economic downturn as its electronic measurement business, this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.